NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Authors
Keywords
Breast cancer, Brain metastasis, PEGylated irinotecan, NKTR-102
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-10-14
DOI
10.1186/s12885-015-1672-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
- (2014) Ute Hoch et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Novel Preclinical Method to Quantitatively Evaluate Early-Stage Metastatic Events at the Murine Blood-Brain Barrier
- (2014) C. E. Adkins et al. Cancer Prevention Research
- Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,®/Doxil®—A Cerebral Open Flow Microperfusion Pilot Study
- (2014) Thomas Birngruber et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors
- (2014) Charles O Noble et al. Nanomedicine
- Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)
- (2014) Pieter J. Gaillard et al. PLoS One
- CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
- (2013) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position
- (2013) J C Kalvass et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Advances in therapy for melanoma brain metastases
- (2013) Jaclyn C. Flanigan et al. CLINICS IN DERMATOLOGY
- Treatment of breast cancer brain metastases
- (2013) Silvia Hofer et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Innovative Therapeutic Strategies in the Treatment of Brain Metastases
- (2013) Maria Caffo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009
- (2013) Rebecca H. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Passive Tumor Targeting of Renal-Clearable Luminescent Gold Nanoparticles: Long Tumor Retention and Fast Normal Tissue Clearance
- (2013) Jinbin Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
- (2013) Ahmad Awada et al. LANCET ONCOLOGY
- Brain metastases in HER2-positive breast cancer
- (2013) Nancy U Lin LANCET ONCOLOGY
- Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model
- (2013) Rajendar K. Mittapalli et al. MOLECULAR CANCER THERAPEUTICS
- Brain Metastases: Can We Do More?
- (2013) Francesco Tomasello et al. World Neurosurgery
- P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model
- (2013) Chris E. Adkins et al. Frontiers in Pharmacology
- The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
- (2012) Hiroshi Maeda et al. ADVANCED DRUG DELIVERY REVIEWS
- A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
- (2012) G. S. Jameson et al. CLINICAL CANCER RESEARCH
- Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
- (2012) Virginia Zabaleta et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
- (2011) M. Verreault et al. JOURNAL OF CONTROLLED RELEASE
- Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
- (2011) Anna Niwińska et al. JOURNAL OF NEURO-ONCOLOGY
- Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts
- (2011) L. P. Serwer et al. NEURO-ONCOLOGY
- The accuracy of cancer mortality statistics based on death certificates in the United States
- (2010) Robert R. German et al. Cancer Epidemiology
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Delivering nanomedicine to solid tumors
- (2010) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
- (2008) A Régina et al. BRITISH JOURNAL OF PHARMACOLOGY
- Brain metastases: current management and new developments
- (2008) Riccardo Soffietti et al. CURRENT OPINION IN ONCOLOGY
- Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats
- (2008) Tripta Bansal et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started